Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amgen’s leukemia drug gets conditional European approval

European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments. The U.S. Food and Drug Administration in December approved Blincyto for acute lymphoblastic leukemia (ALL), which has few treatment options once a patient has relapsed. Blincyto is a so-called bispecific antibody, […]

Read More »

AbbVie scraps Galapagos deal to focus on own arthritis drug

AbbVie Inc said its experimental drug improved symptoms of rheumatoid arthritis in mid-stage studies and scrapped plans to buy rights to a similar treatment from Belgium’s Galapagos NV. Galapagos shares were down 27 percent at 40.20 euros in Amsterdam. AbbVie shares rose 2 percent to $57.66 in early trading on Friday. Analysts said the drug’s […]

Read More »

Roche skin cancer combination therapy gets EU panel backing

Roche is expecting the European Commission this year to issue a final decision on a drug combination to treat advanced skin cancer, based on a drug panel’s positive opinion made public on Friday.   The European Union’s Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for Cotellic, when used […]

Read More »

Novartis’ new heart drug on track for approval in Europe

Novartis AG’s new heart failure drug Entresto is on track to be approved for use in Europe by the end of the year after it received the backing of EU regulators, the company said on Friday.   Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are […]

Read More »

Novartis’ Top Scientist to Step Down, Taps Harvard Medical School Faculty Member to Drive Oncology Research

BASEL, Switzerland – Swiss pharmaceutical giant Novartis AG (NVS) tapped James Bradner, a cancer specialist from Harvard Medical School as the new president of the Novartis Institutes for BioMedical Research (NIBR) in an effort to continue to drive the company’s oncology unit, the company announced this morning.   Bradner, who begins his new position in […]

Read More »

Novo Nordisk successfully completes diabetes drug phase 3a trial

Danish pharmaceutical company Novo Nordisk has successfully completed the second phase 3a trial with its diabetes drug semaglutide, it said on Friday. “We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycemic control and greater weight loss than 2.0 mg exenatide once-weekly,” chief science officer Mads […]

Read More »

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology     September 24, 2015 05:00 PM Eastern Daylight Time   DARMSTADT, Germany & NEW YORK–(BUSINESS WIRE)–As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the […]

Read More »

Former RCW McCann Partners Back Together in New Agency

After almost two years apart and almost 18 years to the day that they founded their first healthcare ad agency, the partners who created Regan Campbell Ward – Maureen Regan, Richard Campbell, and Brendan Ward – are together again. Regan introduced the new agency, MRB Partners, in a short announcement today. “In founding MRB we […]

Read More »

Psychiatrists group warns DOJ insurance mergers could hurt care

The American Psychiatric Association warned U.S. antitrust regulators this month that two proposed health insurance deals could worsen access to mental health care services, adding to public opposition from several prominent doctor groups. Anthem Inc would become the largest U.S. health insurer through a proposed $47 billion acquisition of Cigna Corp, announced in late July. […]

Read More »

Industry Veteran Named President of Guidemark Health

Guidemark Health appoints Vic Zambrotta President September 21, 2015 (Parsippany, NJ) – Guidemark Health, in furtherance of its strategy to meld big industry talent with a nimble agency model, has named Vic Zambrotta as President. Zambrotta brings more than 30 years experience in healthcare sales, marketing, and communications to Guidemark Health and its clients. Immediately […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom